2024 年第 1 期 第 19 卷

Janus激酶抑制剂在皮肤病中应用的研究进展

Research progress on the application of Janus kinase inhibitors in dermatosis

作者：柴淑芳1 李俊琴2 张志祥1 李新华2

英文作者：Chai Shufang1 Li Junqin2 Zhang Zhixiang1 Li Xinhua2

单位：1山西医科大学第九临床医学院，太原030009；2山西医科大学附属太原市中心医院皮肤科，太原030009

英文单位：1The Ninth Clinical College of Shanxi Medical University Taiyuan 030009 China; 2Department of Dermatology Taiyuan Central Hospital Affiliated to Shanxi Medical University Taiyuan 030009 China

关键词：皮肤病；Janus激酶抑制剂；Janus激酶/信号转导和转录激活因子信号通路

英文关键词：Dermatosis;Januskinaseinhibitors;Januskinase/signaltransducerandactivatoroftranscriptionsignalingpathway

• 摘要：

• Janus激酶（JAK）抑制剂是一种抑制JAK/信号转导和转录激活因子（STAT）信号通路的药物，可选择性抑制JAK家族，近几年已成为治疗许多炎症性皮肤病的新方案。JAK/STAT通路是一种细胞内信号通路，细胞因子通过该通路引起疾病。使用JAK抑制剂可能是治疗此类疾病的有用策略。本文对JAK抑制剂治疗皮肤病的机制、疗效及不良反应进行综述。

• Janus kinase (JAK) inhibitors are drugs that inhibit the JAK/signal transducer and activator of transcription (STAT) signaling pathway, selectively inhibiting the JAK family. In recent years, it has become a new treatment for many inflammatory dermatosis. The JAK/STAT pathway is an intracellular signaling pathway through which cytokines cause disease. The use of JAK inhibitors may be a useful strategy for the treatment of such diseases. This article reviews the mechanism, efficacy and adverse reactions of JAK inhibitors in the treatment of dermatosis.